Tissue Procurement Core Ready access to both benign and malignant tissue is a valuable resource for cancer investigators. The Tissue Procurement Core is designed to collect and store high quality tissue specimens from a variety of sources and make these available to HCCC investigators based on the science proposed. The Core insures that these activities are performed in compliance with all rules and regulations covering such activity. The Core and its personnel work in cooperation with clinicians from various departments to: 1) Identify and consent patients from whom collection may be appropriate. 2) Work closely with appropriate individuals in the Surgical Pathology Laboratory to insure adequate patient care while maximizing the number of collected specimens 3) Enter information about specimens into a secure data base and store appropriately 4) Implement rigorous quality control procedures 5) Distribute available tissue to investigators for high quality cancer research The HCCC and University of lowa CTSA are collaborating to further strengthen access to biospecimens. The Tissue Procurement Core has implemented CaTISSUE to enhance the informatics infrastructure for Tissue Procurement, and is working to develop an approach to obtaining consent at the time of registration to the medical center, and link tissues with deidentified clinical data, that will further enhance the utility of tissue for HCCC investigators.

Public Health Relevance

The availability of human cancer and normal tissue is vital for basic and translational cancer research. The Tissue Procurement Core provides a centralized, efficient approach to providing this invaluable resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-12
Application #
8381323
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-03
Budget End
2013-03-31
Support Year
12
Fiscal Year
2012
Total Cost
$88,296
Indirect Cost
$32,874
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Meyerholz, David K; Ofori-Amanfo, Georgina K; Leidinger, Mariah R et al. (2017) Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. J Histochem Cytochem 65:607-618
Ebbert, Jon O; Little, Melissa A; Klesges, Robert C et al. (2017) Step Care treatment for smoking cessation. Health Educ Res 32:1-11
Sfeir, J G; Drake, M T; LaPlant, B R et al. (2017) Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J 7:e526
Mohiuddin, I; Allen, B G (2017) A Single-Institution Experience in Treating Thymic Carcinoma. Int J Radiat Oncol Biol Phys 98:229
Miller, Benjamin J (2017) CORR Insights®: Is It Appropriate to Treat Sarcoma Metastases With Intramedullary Nailing? Clin Orthop Relat Res 475:218-220
Huang, Jianguo; Chen, Mark; Whitley, Melodi Javid et al. (2017) Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. Nat Commun 8:15999
Jethava, Yogesh S; Barlogie, Bart; Tricot, Guido J (2017) Drug Combinations with Transplantation for Myeloma. N Engl J Med 377:91-2
Gilbertson-White, Stephanie; Bohr, Nicole; Wickersham, Karen E (2017) Conducting Biobehavioral Research in Patients With Advanced Cancer: Recruitment Challenges and Solutions. Biol Res Nurs 19:481-490
Rogers, Laura M; Mott, Sarah L; Smith, Brian J et al. (2017) Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. Clin Cancer Res 23:954-961
Eppsteiner, Robert W; Fowlkes, Jonathan W; Anderson, Carryn M et al. (2017) Aggressive Salivary Malignancies at Early Stage: Outcomes and Implications for Treatment. Ann Otol Rhinol Laryngol 126:525-529

Showing the most recent 10 out of 831 publications